Application of in Vivo Splitting Technique in Adult Liver Transplantation

Application of in Vivo Splitting Technique of Brain-dead Donor Liver in Adult Liver Transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06925828

Enrollment

500

Registered

2025-04-13

Start date

2021-01-01

Completion date

2025-12-31

Last updated

2025-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Keywords

Split liver transplantation, Whole liver transplantation, Short-term Outcomes, Surgical complications, Morbidity and Mortality

Brief summary

The feasibility of split liver transplantation (SLT) remains controversial. This study aimed to evaluate the outcomes of SLT in adult recipients and to identify specific areas of improvements. A retrospective analysis was conducted on adults who underwent full size SLT between January 2021 and December 2023. The short-term outcomes of these patients who underwent SLT were compared with those of patients who underwent whole liver transplantation (WLT) during the same period.

Interventions

OTHERNo intervention

No intervention

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

16 Years to 75 Years

Healthy volunteers

Inclusion criteria

* For the donor graft: 1. age of 18-60 years; 2. BMI of 19-28 kg/m2; 3. hemodynamic stability or use of a single vasoactive drug with a small dosage (norepinephrine ≤ 0.1 μg/kg/min or dopamine ≤ 5 μg/kg/min); 4. liver steatosis ≤ 10%; 5. liver functional indicators (ALT, AST, total bilirubin quantification) ≤ 3 times the normal value; 6. blood sodium ≤ 160 mmol/L; For the SLT recipients 1. Patients who had registered in the China Organ Transplant Response Systems. 2. Initial liver transplantation. 3. Graft-to-Recipient Weight Ratio (GRWR) ≥ 1%.

Exclusion criteria

* For the donor graft 1. uncontrollable infection 2. significant vascular and biliary variation. For the recipients 1. Severe portal hypertension. 2. Significant vascular variation.

Design outcomes

Primary

Measure	Time frame	Description
Overall survival	2021.01.01-2025.12.31	the overall survival of liver transplant recipient during study period

Secondary

Measure	Time frame	Description
Postoperative complications	2021.01.01-2025.12.31	Postoperative complications of liver transplant recipient during study period

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026